Cardiff Oncology (CRDF): Latest 2026 Update — What You Need to Know

Cardiff Oncology ($CRDF) shares have stabilized near $1.73 after a turbulent Q1, with investors now laser-focused on the upcoming "KOL Discussion" on March 25 and the April AACR data presentation. While the stock has faced a 35.94% YTD decline, Wall Street analysts maintain a "Moderate Buy" consensus, citing a massive 487% forecasted upside if its lead candidate, onvansertib, hits its registrational milestones.

Key Facts Box

• Current Stock Price: $1.73 (as of March 24, 2026)
• Consensus Rating: Moderate Buy (7 Analysts)
• Average Price Target: $10.10 (Implied +484% upside)
• Cash Runway: $58.3M (Estimated to fund operations into Q1 2027)
• Clinical Focus: Lead asset onvansertib for 1L RAS-mutated mCRC
• Market Cap: Approximately $118.27 Million

Timeline of Major Events

• March 25, 2026: Scheduled Key Opinion Leader (KOL) Webinar at 4:30 PM ET to discuss the future of mCRC management.
• March 19, 2026: Breaking: Announced upcoming presentation of preclinical data at the AACR Annual Meeting (San Diego) showing onvansertib reverses resistance in breast cancer models.
• Feb 24, 2026: Reported FY2025 results and confirmed a robust 72.2% Objective Response Rate (ORR) for the 30mg onvansertib combo trial.
• Jan 27, 2026: Sudden Leadership Change and trial narrowing caused a 32% single-day plunge, as the company pivoted exclusively to first-line colorectal cancer.

Analysis: The "Onvansertib Only" Pivot

Cardiff Oncology made a strategic, albeit painful, decision in early 2026 to narrow its focus. By prioritizing the 30mg dose of onvansertib for first-line RAS-mutated mCRC, the company is aiming for a "registrational program"—essentially their final hurdle before FDA approval.

What This Means For You: The "Management Pivot" risk has already been priced in. If the upcoming KOL discussion on March 25 reinforces the 72.2% ORR and 0.37 Hazard Ratio, the current sub-$2 price point could represent a significant "value gap" before the registrational trial begins in H2 2026.

Analysis: Financial Runway & Dilution Risk

Update: Cardiff ended 2025 with $58.3M in cash. Piper Sandler recently lowered their price target from $10 to $6, noting that while the cash lasts until Q1 2027, the path to approval (now pushed to 2030) will likely require further capital raises.

What This Means For You: Expect volatility. While the technical "Strong Buy" sentiment exists, the -71.5% Return on Equity (ROE) means CRDF is a high-risk, high-reward biotech play. You are essentially betting on the drug's efficacy vs. the company's ability to avoid heavy dilution.

Market & Community Impact

Stocktwits and retail sentiment remain mixed to bearish due to the YTD price action. However, institutional ownership sits at 16.29%, and insider sentiment has turned positive following open-market purchases.

The "Bull Case" on Stocktwits rests on the $10.10 price target. If onvansertib proves to be a "first-in-class" PLK1 inhibitor, Cardiff becomes a prime acquisition target for Big Pharma looking to bolster their oncology pipelines.

What to Watch Next

1. April 19, 2026 (AACR Meeting): Watch for the full poster presentation on onvansertib’s ability to reverse resistance in HER2-low breast cancer models. This could reignite interest in the drug’s broader applications beyond colorectal cancer.
2. H1 2026 Final Data: The company expects final data and the official registrational plan for CRDF-004 by the end of June.
3. CEO Search: The appointment of a permanent CEO and CFO will be a major catalyst for institutional trust.

FAQ

Is CRDF a good stock to buy in 2026?

Wall Street thinks so, with an average target of $10.10. However, technical signals (MACD/Moving Averages) currently suggest a "Sell" or "Hold" until a bottom is confirmed.